The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, tolerability, and immunogenicity of single inhaled dose of AZD8630 administered in adolescent participants with asthma as well as the safety and performance of the dry powder inhaler.

This is a Phase 1, open label, single dose study that will be conducted in adolescent participants with asthma where the participants will receive AZD8630 administered via dry powder inhaler.

The study will be comprised of:

• A screening period.
• A treatment period.
• A post treatment period.
• A final Follow-up visit.

Key Inclusion Criteria:

• Physician prescribed daily use of asthma medication.
• Pre-bronchodilator Forced expiratory volume in one second (FEV1) ≥ 50% of the predicted normal value.
• Asthma control questionnaire-5 (ACQ-5) < 1.5 at Screening and Study Day 1.

Key Exclusion Criteria:

• History of any clinically important disease or disorder.
• History of any chronic respiratory disorders (except asthma).
• Acute exacerbation of asthma within 4 weeks of Screening.
• Life -threatening asthma.
• Completed treatment for respiratory infection with antibiotics within 4 weeks of Screening.
• History of acquired or inherited immunodeficiency disorders.
• Oral immunotherapy, including stable maintenance dose allergen-specific oral immunotherapy.

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secureresearchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.